The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors.
I. Garrido-Laguna
No relevant relationships to disclose
R. Kurzrock
Honoraria - Genentech; Pfizer
Research Funding - Roche
J. J. Wheler
No relevant relationships to disclose
G. S. Falchook
No relevant relationships to disclose
S. A. Piha-Paul
No relevant relationships to disclose
S. Fu
No relevant relationships to disclose
A. Naing
No relevant relationships to disclose
C. Hinojosa
No relevant relationships to disclose
R. Mistry
No relevant relationships to disclose
A. Scamardo
No relevant relationships to disclose
K. S. Culotta
No relevant relationships to disclose
S. Ekmekcioglu
No relevant relationships to disclose
S. Wen
No relevant relationships to disclose
L. H. Camacho
No relevant relationships to disclose
S. P. Ivy
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose